

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 1, 2017**

**OCULAR THERAPEUTIX, INC.**  
(Exact Name of Company as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-36554**  
(Commission  
File Number)

**20-5560161**  
(IRS Employer  
Identification No.)

**34 Crosby Drive, Suite 105  
Bedford, MA 01730**  
(Address of Principal Executive Offices) (Zip Code)

Company's telephone number, including area code: **(781) 357-4000**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Ocular Therapeutix held its Annual Meeting of Stockholders on June 1, 2017. The following is a summary of the matters voted on at that meeting.

- (a) Ocular Therapeutix's stockholders elected Amarpreet Sawhney, Ph.D., Bruce Peacock and Jeffrey S. Heier, M.D. as Class III directors to serve until the 2020 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such Class III directors were as follows:

Name	Votes For	Votes Withheld	Broker Non-Votes
Amarpreet Sawhney, Ph.D.	12,899,564	2,127,299	9,511,468
Bruce Peacock	12,906,842	2,120,021	9,511,468
Jeffrey S. Heier, M.D.	12,661,305	2,365,558	9,511,468

- (b) Ocular Therapeutix's stockholders ratified the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the current fiscal year. The result of the stockholders' vote with respect to such ratification were as follows:

For	Against	Abstain	Broker Non-Votes
24,457,147	75,696	5,488	0

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OCULAR THERAPEUTIX, INC.

Date: June 1, 2017

By: /s/ George Migausky  
George Migausky  
Interim Chief Financial Officer  
(Principal Financial and Accounting Officer)